首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   37篇
  免费   3篇
儿科学   1篇
基础医学   1篇
临床医学   2篇
特种医学   1篇
外科学   1篇
综合类   6篇
预防医学   4篇
药学   11篇
中国医学   13篇
  2023年   1篇
  2022年   6篇
  2021年   3篇
  2020年   3篇
  2019年   3篇
  2017年   1篇
  2016年   1篇
  2015年   2篇
  2014年   2篇
  2013年   5篇
  2012年   2篇
  2011年   1篇
  2010年   1篇
  2009年   1篇
  2008年   1篇
  2007年   2篇
  2002年   1篇
  2001年   1篇
  1998年   1篇
  1994年   2篇
排序方式: 共有40条查询结果,搜索用时 15 毫秒
1.
背景 物理降温方法是中枢性高热患者的主要降温方法,目前临床上常用的物理降温方法效果报道不一,且存在较明显的并发症。目的 探讨一种新型低温静脉输液装置(国家实用新型专利,专利号:ZL 2014 2 0070586.4)对中枢性高热患者进行物理降温治疗的效果及安全性。方法 选取2015-2019年佛山市中医院重症医学科收治的中枢性高热患者93例,采用随机数字表法将其分为对照组(n=29)、普通静脉降温组(n=32)和应用降温装置组(n=32)。对照组给予基础治疗及体表物理降温,普通静脉降温组在对照组的基础上予以静脉输注低温液体(由冰箱冷藏4 ℃),应用降温装置组则在对照组的基础上采用新型低温静脉输液装置输注室温液体。检测三组患者治疗前、治疗24 h及治疗48 h后的凝血功能指标:纤维蛋白原(FbgC)、活化部分凝血活酶时间(APTT)、凝血酶原时间(PT)及血小板计数(PLT);观察寒战、心律失常、皮肤受损等并发症发生率;测量治疗前及治疗2、4、8、12、24、48 h的肛温;评估治疗1周后格拉斯哥昏迷量表(GCS)评分;电话随访患者治疗28 d病死率。结果 治疗方法和时间对FbgC、APTT、PT及PLT不存在交互作用(P>0.05);治疗方法和时间对FbgC、APTT、PT及PLT主效应均不显著(P>0.05)。应用降温装置组寒战发生率低于对照组和普通静脉降温组,皮肤受损发生率低于对照组(P<0.017)。治疗方法和时间对肛温存在交互作用(P<0.05);治疗方法和时间对肛温主效应均显著(P<0.05);其中应用降温装置组治疗2、4、8、12、24、48 h的肛温均低于对照组和普通静脉降温组(P<0.05)。治疗1周后应用降温装置组GCS评分高于对照组和普通静脉降温组(P<0.05)。三组患者治疗28 d病死率比较,差异无统计学意义(P>0.05)。结论 采用新型低温静脉输液装置对中枢性高热患者进行物理降温治疗具有快速且稳定的降温效果,且其并发症发生率低,可广泛应用于临床降温治疗。  相似文献   
2.
目的 通过挖掘中药复方专利中治疗抑郁的用药规律,为中药新方研发和临床应用提供参考。方法 登录中国专利公布公告网站,检索治疗抑郁的中药复方专利数据,采用中医传承辅助平台(V2.5)建立数据库,并对其进行频次统计、关联规则、复杂网络及熵层次聚类分析。结果 纳入2003年-2018年治疗抑郁的中药复方专利343项,涉及药物685味,最常用单味药为柴胡,高频药物归经以心、肝两经为主,功效多为安神、补气、活血、理气;最常用药对为白芍-柴胡,最常用角药为当归-白芍-柴胡;置信度最高的关联规则为“甘草,当归,茯苓→柴胡”;核心药物为柴胡、白芍、郁金、茯苓、甘草等; 熵层次聚类分析得到核心组合20个,新处方10首。结论 治疗抑郁的中药复方专利中常见证型为“肝郁脾虚证”,以疏肝解郁健脾为主要治则,同时根据症状辅以安神、益气、理气、活血、燥湿、清热等治法,多以逍遥散为基础方,常配伍心、肝两经药。  相似文献   
3.
4.
The English Court of Appeal Judgment in Bristol-Myers Squibb Company vs. Baker Norton Pharmaceuticals and Napro Biotherapeutics2 has restricted the scope of second medical use claims in England to inventions for distinctly different therapeutic applications, thereby excluding inventions for new modes of administration or ones with inherent therapeutically beneficial effects. The Court of Appeal’s decision cuts across a body of European and international decisions and limits 3 to second non-medical uses. In coming to their decision, the Court of Appeal considered in detail the European decisions of 4 and Mobil but declined to overrule them. How the Court of Appeal’s decision will impact on decisions by Courts in other jurisdictions, in particular in Europe, remains to be seen. However, the English Courts have recently considered two further ‘second medical use claim’ patents: the Court of Appeal in American Home Products vs. Novartis5 and the High Court in Lilly Icos 6. And although these cases do not turn on the fact that they are second medical use claim patents, the Courts do not appear to be deviating from the Court of Appeal decision in Bristol-Myers Squibb. Nevertheless, what is clear, is that the Court of Appeal in Bristol-Myers Squibb omitted to address the public policy issue regarding the extent to which valuable and costly research and development in new therapeutic applications of known medicines, exemplified by the Bristol-Myers Squibb case, should be rewarded by the grant of further patents. This issue is of concern to the pharmaceutical industry and is one that the English Courts will undoubtedly have to clearly address in the future.  相似文献   
5.
Entomopathogenic fungus belonging to the genus Aschersonia [Sordariomycetes: Hypocreales: Clavicipitaceae] is known for its high virulence against Aleyrodidae and Coccoidea. Its first use as a biological control agent date back to 1921 in Florida, when it was reported to be active against citrus whiteflies. Despite its recognized effectiveness, after a century no formulations based on Aschersonia are available for use as a biopesticide. The main aim of this study was to analyze the available patents and scientific articles involving this genus to understand the current scenario with respect to the scientific and technological development. To accomplish this objective, scientific and patent databases were surveyed, firstly using the terms ‘Entomopathogenic fungi, ‘Aschersonia’, ‘Beauveria’ and ‘Metarhizium’ to understand the overall scenario of scientific and technological production for entomopathogenic fungi. This was followed by a more detailed analysis for the genus Aschersonia. Our study demonstrates that there is little advancement with respect to research and technological development with this fungus. A total of 83 articles and 110 patents were found with the term “Aschersonia” in titles or abstracts. After the exclusion of articles and patents in duplicates, and without Aschersonia as the focus, 18 articles and 21 patents remained. Most of the scientific and technological production obtained described the production of enzymes and mycotoxins, focusing on other biotechnological applications rather than its use as an insecticidal agent. We elucidate possible difficulties for the use of this fungus as a biological control agent and provide a future perspective on its use in biotechnological products.  相似文献   
6.
报告连续使用解毒胶囊(蒲公英、败酱草、鳖甲、双花、连翘等)9个月治愈未婚乳腺增生1例。  相似文献   
7.
观察自主研发专利产品泪道吻合器治疗暴力伤致泪小管断离的临床价值。对89例泪道吻合器植入术,术后8周无吻合器提前脱落,87例冲洗泪道通畅,无角膜上皮擦伤及泪小点移位、裂伤,手术成功率97.752%。泪道吻合器植入简单,最大限度减轻患者术中术后痛苦,美观,安全有效。  相似文献   
8.
目的 应用数据挖掘和网络药理学方法探索治疗骨质疏松症的专利中药复方的用药规律和潜在机制,为临床诊治及新药研发提供参考。方法 以国家知识产权局的授权专利为资料来源,筛选治疗骨质疏松症的中药复方,使用整合药理学平台(TCMIP V2.0)分析筛选复方的中药频次统计、对药角药分析、性味归经分析等;用IBM SPSS Modeler 18.0软件对所录中药进行关联规则分析并制图;基于TCMIP V2.0平台对药物-疾病关联网络进行深入挖掘。结果 纳入中药复方专利数据299条,共涉及中药670味;挖掘核心药物为:熟地黄、杜仲、淫羊藿、枸杞子、骨碎补、山药;核心药物组合通过42个有效化学成分、92个核心靶标、25条通路发挥治疗骨质疏松症的药理作用。结论 以核心药物作用分子机制为依据,中药复方治疗骨质疏松症多采用补益气血阴阳兼以活血之法,临证可加以优化借鉴。  相似文献   
9.
随着中药现代化进程的推进,纳米技术在中药领域的应用也日益受到重视。本文简述了中药领域中药纳米技术的专利现状,指出我国中药知识产权保护意识薄弱;分析了中药纳米技术相关专利的发展特点和方向,指出应加强产学研结合,加快专利成果的产业化进程。  相似文献   
10.
The SARS‐CoV‐2 (COVID 19) paroxysm is a dominant health exigency that caused significant distress, affecting physical and mental health. Increased mortality, a stressed healthcare system, financial crisis, isolation, and new living and working styles enhanced societal commiseration leading to poor health outcomes. Though people try to maintain good physical health but unfortunately the mental affliction is still ignored. Poor psychological health has emerged as a burgeoning social issue and demands attention. Henceforth, the fundamental objective of this review article is to collate information about COVID-linked physical and psychological agony in diverse population groups with related symptoms and accessible diagnosis techniques. Recent studies have unraveled the fragile mental states of people who have either contracted COVID 19 or had near and dear ones falling prey to it. The impact of the epidemic on the human mind both in short and long-term, with possible risk and preventive factors together with suggested solutions for maintaining good health have also been discussed here. It also enlists the available medications, vaccines and investigational research in the form of patents and clinical trials. This article can be taken as an updated information sheet for COVID 19, accompanied by its management techniques with special emphasis on coping strategies for mental health. Further, it may also assist the policymakers to devise approaches that could enable the public to overcome the pandemic-driven adversity not only in the given situation but also futuristically.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号